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Abstract
Orthotopic heart transplant is recognized as the gold standard for the treatment of end-
stage heart disease. However, there is a perennial shortage of donor organs. Left ven-
tricular assist devices (LVAD) represent a revolutionary tool for temporizing heart failure 
that is refractory to medical management until a suitable organ becomes available. This 
review highlights the LVAD as a tool for bridging to transplant. The history of the LVAD 
and its use in heart transplantation is described, as well as the current indications for use 
in the general heart transplant candidate as well as for selected subpopulations. It also 
highlights the major complications of LVAD use, advancements in the field, and selected 
current controversies related to the LVAD as bridge-to-transplant therapy.
Keywords: heart transplantation, ventricular assist devices, LVAD, mechanical 
circulatory support, bridge to transplant
1. Introduction
End-stage heart disease represents a worldwide epidemic, with over 6.6 million people 
affected in the United States alone. The prevalence of end-stage heart disease is increasing due 
the aging population in the US and Europe, as well as improved management and therefore 
increased survival of other cardiac diseases. It is estimated that upwards of 600,000 new cases 
diagnosed each year. Furthermore, the incidence of end-stage heart disease is estimated to 
increase at a rate of 25% by the year 2030 [1]. The disease is associated with significant morbid-
ity and mortality; 50% of patients in this population will die within 4 years; in the subset of 
patients hospitalized with acute heart failure, 40% will be readmitted or die within 1 year. In 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
suitable candidates, heart transplantation is the gold standard therapy for this disease, provid-
ing the best opportunity for long-term survival and improved quality of life. However, organs 
that are suitable for transplantation are a scarce resource. This approach is limited for many 
years by availability of donor hearts as only approximately 2300 orthotopic heart transplants 
are performed each year; the pool of patients who are candidates for heart transplantation 
continues to increase, with no evidence that this trend will reverse any time soon. As a result, 
the management of end-stage heart failure with cardiac transplantation must increasingly rely 
on an armamentarium of medical and mechanical tools for bridging patients to transplant.
In particular, the introduction of the left ventricular assist devices (LVAD) has become instru-
mental in the management of the heart failure patient who is refractory to medical therapy; in 
their current iteration their use has been associated with a decrease in mortality and an improve-
ment in the quality of life among suitable patients awaiting transplantation. In this review, we 
will discuss a brief history of the LVAD as it relates to heart transplantation, in particular the 
evolution of available devices, and the current indications for use. It bears highlighting that 
LVAD implantation is associated with significant device-related complications and these are 
described in detail. Lastly, we will discuss several topics of current controversy and areas of 
evolution within the field of mechanical device support of the heart transplant candidate.
2. History
2.1. Early LVAD devices
A timeline of advances in LVAD technology and in heart transplantation is included in Figure 1. 
In the early 1950s, open-heart surgery was associated with high mortality as a result of the fre-
quent complication of postcardiotomy shock, a problem for which there was little answer at 
the time. In order to combat this problem, cardiopulmonary bypass as a means of bridging to 
recovery became a major experimental target. Initial clinical use of a cardiopulmonary bypass 
system for temporary circulatory support may be attributed to the work of Gibbon in 1953. 
This work into circulatory support would pave the way for future innovation in development 
of intracorporeal left ventricular assist devices.
Figure 1. Timeline of advances in mechanical cardiac support and heart transplantation.
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In 1964, the National Heart, Lung, and Blood Institute established the Artificial Heart Program 
with the express goal of developing therapies that would allow for the bridging of patients 
with postcardiotomy shock to recovery. Liotta and Crawford at the Texas Heart Institute are 
identified as performing the first LVAD implantation in 1963. The index patient was success-
fully weaned from the device from a cardiopulmonary standpoint; however, he ultimately 
succumbed to neurologic complications. Further modifications by Liotta and DeBakey led 
to first use of a paracorporeal LVAD for bridge to recovery after double valve replacement in 
a 37-year old female patient in 1966. After 10 days of support, the patient recovered and the 
LVAD was explanted without complication; the patient ultimately survived another 6 years 
prior to death due to a motor vehicle accident.
Concurrent with these initial models for mechanical circulatory support for bridge to recov-
ery, the innovative concept of orthotopic heart transplant was also undergoing experimentation. 
This therapy was first demonstrated in animal models by Lower and Shumway in 1966, and 
subsequently the first human-to-human heart transplant performed by Barnard in 1967. With 
the advent of this new therapy, an alternative use for the LVAD besides bridge to recovery was 
identified. In 1969, Cooley implanted the first temporary total artificial heart into a patient as 
a bridge to cardiac donor availability for heart transplantation; his patient survived with total 
artificial heart support for over two and a half days prior to transplantation but died in the early 
postoperative period due to pneumonia. Mechanical complications associated with the total arti-
ficial heart led to a greater focus on the LVAD as preferred mechanical support after open heart 
surgery; in 1975 the first clinical trials of LVADs as temporary support after open-heart surgery 
were initiated, and in 1978, the first LVAD as bridge to transplant was used by Dr. Frazier.
Advances in technology and better understanding of cardiac flow dynamics have contributed to 
the evolution of the rapid VAD as a mechanical device. Early VADs made use of implanted pneu-
matic pump-driven volume displacement technology to drive forward flow. These first generation 
LVADs, mimic the function of the heart. The first generation of volume displacement pumps had 
multiple complex moving parts, with one-way valves and a flexible pumping chamber. Because 
of this, the devices were susceptible to breakdown and failure, among other complications.
The Pierce-Donachy VAD was a displacement device that was developed at Penn State 
University in 1970; it would serve as the prototype for Thoratec pulsatile-low VADs utilizing 
a pusher-plate system which could be implanted either paracorporeally (Thoratec pVAD) 
or intracorporeally (iVAD). This membrane-displacement technology was also used in the 
development of the 1978 Model 7 LVAD, later modified to the Heartmate implantable pneu-
matic and first used in clinical trials in 1986 [2]. A further evolution would lead to a variation 
known as the HeartMate VE (vented electric), and subsequently the HeartMate XVE (extended 
vented electric). By 1990, the FDA had given approval of LVAD as a bridge to heart transplant 
therapy, and a 1999 single-institution retrospective review of the use of the HeartMate XVE 
in bridge to transplant identified 75% of candidates as undergoing successful transplantation 
after a mean LVAD use of 106 days [3].
The success of LVAD as a bridge to led to clinical trials exploring the use of the LVAD as dura-
ble therapy. Perhaps the most well-known of the major clinical trial assessing the functional-
ity of a LVADs for long-term use was the Randomized Evaluation of Mechanical Assistance 
for the Treatment of Congestive Heart Failure (REMATCH) trial of 2001 [4]. Here, patients 
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with end-stage heart failure who were not candidates for heart transplantation underwent 
either LVAD implantation using the HeartMate VE or received maximal medical therapy; 
these two groups were compared for long-term complication and mortality outcomes. In this 
landmark study, survival among the VAD placement group was found to be 52% compared 
to 25% in the medical management group at 1 year, with a further 48% relative risk reduction 
in mortality over the 2-year study period. Additionally, the LVAD cohort was also highlighted 
as having improved quality of life.
However, we highlight the REMATCH study here primarily because it also identified a num-
ber of serious complications and limitations related to the use of LVAD support as durable 
therapy. The pulsatile flow HeartMate VE first-generation LVAD used in this study was found 
to have a rate of serious complications 2.35 times greater than in medical therapy group. 
Indeed, this group carried a relative risk of stroke 4.35 times that of the medical group. 
Intraperitoneal placement of the large LVAD device was associated with early satiety, and 
the extensive surgical dissection required for implantation was associated with a significant 
bleeding and infection risk. Over 21% of patients ultimately required device replacement. As 
a result, and primarily due to the long-term risk of infection and mechanical failure, the-year 
survival in the LVAD group was limited to 23% [4].
2.2. The modern era of LVAD
Continuous-flow devices making use of either an axial flow model (second-generation 
LVADs) or a centrifugal flow model (third-generation) were the next innovation in LVAD 
performance. The second generation has key mechanical advantages compared prior, includ-
ing elimination of valves and chambers and the introduction of an internal rotor suspended 
by contact bearings. These alterations were theorized to lead to a decreased rate of complica-
tions, due in part to their fewer moving parts. However, analysis of outcomes has also shown 
that the direct contact between the bearings and blood in second generation LVADs serves as 
an area of thrombosis formation.
The second generation of LVADs were implemented into clinical practice in the late 1990’s and 
demonstrated an acceptable safety profile for bridge to transplant when compared to existing 
pulsatile-flow devices despite the aforementioned higher-than-expected incidence of pump 
thrombosis. Approval of these later-generation LVAD’s was primarily derived from three land-
mark clinical trials either directly comparing the pulsatile HeartMate XVE with the continuous 
flow HeartMate II [5], or with the use of historical controls to compare their outcomes [6, 7]. The 
earliest of these studies was a prospective multicenter trial of 133 patients with end-stage heart 
failure who underwent VAD therapy as a bridge to transplant [6]. Among these participants, a 
total of 100 (75%) survived to the principal aggregate outcome of either heart transplant, cardiac 
recovery, or survival to the end of the study; of note, of those patients on persistent mechanical 
support through the study, there was a 1-year survival of 67%. There was no control group in 
this study, but survival was compared favorably with a historical control of 53% 1-year survival 
among patients using the pulsatile-flow HeartMate XVE as a bridge to transplant. A follow-
up study identified further improvements in survival among those using these devices, with 
that improvement being attributed to increased device experience [7]. Another major study 
evaluating the morbidity benefit of continuous over pulsatile-flow VADS identified an 1-year 
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endpoint of stroke, reoperation, or mortality-free VAD use of 46% in the continuous flow cohort 
compared to 11% in the pulsatile flow cohort [5]. Further multi-center reporting of adverse 
events between the two groups also demonstrated a statistically significant reduction in infec-
tion, neurologic dysfunction, renal and respiratory dysfunction, and need for device replace-
ment resulting from mechanical failure among those patients with continuous-flow LVADs.
The third generation of LVADs relies on centrifugal continuous flow. The key technologi-
cal advancement in the third generation LVAD is the implementation of noncontact bear-
ings, which utilize magnetic levitation and decrease the incidence of thrombosis due to the 
lack of contact. In recent years, much of the data regarding the comparative effectiveness of 
LVADS stems from the Interagency Registry of Mechanically Assisted Circulatory Support 
(INTERMACS) organization, which serves as a multi-center registry data registry. From this, 
we identify >20,000 patients that have been implanted with an LVAD nationwide [8]. A 2011 
multicenter trial by Strueber et al. [9] identified survival rates during support in patients 
bridged to transplant at being 84 and 79% at 1 and 2 years post-transplant, respectively. The 
ADVANCE multicenter clinical trial identified greater than 86% survival at 1 year among 
those patients using a third generation VAD, with improved functional capacity, quality of 
life, and a decreased complication profile. Under a continued access protocol of the latter 
study, the use of third generation VADs as a bridge to transplant continues to demonstrate a 
high preoperative survival rate despite a low rate of transplant. Although frequent hospital-
izations due to device-related issues and other complications are noted, rates of adverse event 
rates are similar to or improved from those observed in historical bridge-to-transplant trials, 
despite longer exposure times due to longer survival and lower transplant rates.
Recent advances include the approval of the HeartMate III as a bridge to transplantation. This 
is an intrapericardial centrifugal-flow pump making use of pump rotor that is levitated and 
completely suspended by magnetic forces. This is designed to minimize shear stress, stasis, 
and platelet activation compared to earlier LVAD models. Its unique design allows for func-
tioning in the absence of any friction or heat generation; furthermore, it holds the capacity for 
device-initiated pulsatility of flow. The burgeoning evidence from clinical trials have been 
encouraging; results of the Conformité Européene Mark study evaluating the HeartMate IIII 
demonstrated a mortality rate of 18% with low rates of embolic events and no cases of pump 
thrombosis [10] the concurrent MOMENTUM 3 trial further supports a significantly reduced 
rate of bleeding or thrombotic complications among HeartMate III users, with 69% achieving 
complication freedom compared to 55% of HeartMate II users at 1 year [11].
3. Indications for LVAD bridge-to-transplant
3.1. Current outcomes
While left ventricular assist devices are increasingly used in the role of bridge to transplant, 
conflicting data exists regarding outcomes compared to the patients who proceed directly to 
transplant. Outcomes are improving both as a result of greater use of the continuous flow 
device, and as a result of more sophisticated algorithms for dealing with LVAD complica-
tions. Currently, current survival to transplant and post-transplant outcomes appear to be 
Heart Transplantation in the Era of the Left Ventricular Assist Devices
http://dx.doi.org/10.5772/intechopen.76935
49
essentially equal between groups, especially in the absence of LVAD-related complications. 
Graft rejection also appears to be similar in patients who are bridged with LVADs compared 
to those without LVADs.
3.2. General indications
Currently, the European Society of Cardiology guidelines for treatment of end stage heart fail-
ure include the use of left ventricular assist devices as a Class IB recommendation in patient’s 
refractory to medical therapy while waiting for a heart transplant. In addition, the American 
Heart Association has also issued a guidance document describing the use of mechanical 
circulatory support in the setting of bridge to transplant as a Class IB recommendation [12]. 
There is data to suggest that patients bridged to heart transplant with LVAD have higher post-
transplant mortality compared to those without LVADs. However, much of this data stems 
from old risk calculations based on outcomes after implantation of pulsatile flow LVADs. As 
identified above, complication rates improved markedly as these devices have largely given 
way to continuous flow VADs with a more acceptable side-effect profile.
The current indications for heart transplantation include hemodynamically compromised 
patients with New York Heart Association class III-IV, as well as patients with stage D heart 
failure who are in refractory cardiogenic shock and dependent on intravenous inotropic sup-
port to maintain adequate organ perfusion. Further indications include severe angina that 
limits routine activity and is not amenable to revascularization, and recurrent symptomatic 
ventricular arrhythmias refractory to all other therapeutic modalities. Once listed, the cur-
rent United Network for Organ Sharing (UNOS) organ-allocation system gives its highest 
transplant priority status (Status 1A) to those hospitalized patients who dependent on either 
inotropic medical therapy, or mechanical circulatory support such as LVAD support. UNOS 
designates an intermediate priority status (Status 1B) to those patients who are receiving ino-
tropic or mechanical support at home. Patients who have infectious, bleeding, or thrombo-
embolic complications while on VAD support may be advanced to 1A status until the time of 
transplantation; there is an additional discretionary option where patients with LVAD sup-
port may be advanced to Status 1A based on the decision of their transplant team and lasting 
for 1 month before downgrade back to 1B. Most other patients are given standard priority on 
the waitlist (Status 2).
In order to assist with optimal patient selection for placement of an LVAD, the INTERMACS 
registry has developed seven clinical profiles to identify patients. (1) Level 1 includes patients 
who are in critical cardiogenic shock requiring mechanical support. (2) Level 2 includes 
patients who are declining despite inotropic support. (3) Level 3 includes patients who are 
stable on inotropic support. (4) Level 4 includes patients with resting symptoms. (5) Level 5 
includes patients who are intolerant to exertion. (6) Level 6 includes patients who are able 
to engage in limited exertion. (7) Level 7 includes patients who have advanced NYHA III 
heart failure. In the early years of LVAD implementation, the first two profiles (Level 1 and 2) 
comprised 60–80% of the LVAD candidates who were considered to be candidates for bridge 
to transplant. More recently, a shift has occurred in response to improved patient selection 
and risk stratification such that that the majority of patients implanted are now INTERMACS 
3 and 4 profiles. Currently, 80% of patients who are being implanted with LVAD fall within 
INTERMACS Levels 2–4 [13].
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A number of additional risk stratification and preoperative predictive factors have been 
developed to help select LVAD candidates and predict in-hospital mortality. For example, a 
multivariable risk score has been generated from preoperative factors of destination-therapy 
patients, and this highlights risk factors such as low albumin, low platelet count, abnormal 
liver function test or evidence of right ventricular dysfunction [14]. More recently, a risk score 
for LVAD patients was developed which showed that age and center experience were determi-
nants of long-term survival [15]. While conventionally, LVAD placement is increasingly likely 
with increasing severity of INTERMACS profile, the ROADMAP clinical trial has shown that 
early implantation in lower INTERMACS profiles (4–7) outcomes are as favorable as earlier 
trials with improvements in quality of life [16]. Survival patterns from the UNOS database 
suggest that with the current LVAD technology, patients supported with LVAD support as a 
bridge to therapy demonstrate an improved survival while listed for heart transplantation, and 
the use of LVADs as a bridging strategy could potentially improve patient survival while wait-
ing for transplantation, in turn allowing for better allocation of donor hearts [17]. Similarly, 
a 2016 study utilizing the United Network of Organ Sharing (UNOS) database showed those 
patients who underwent LVAD implantation prior to being listed for heart transplantation 
had improved survival compared to those who were medically managed; this survival benefit 
extended to those who were implanted with a LVAD while awaiting heart transplantation [18].
In general, the implementation of the VAD has led to a number of significant effects upon heart 
transplantation and the donor population. (1) There are now a significant number of patients 
with end stage heart failure who would otherwise have died while awaiting emergency trans-
plantation, who are now surviving to have heart transplants performed under non-emergent 
circumstances. This has a profound effect on the pool of available donors as well as the acuity 
of transplant. (2) Cardiogenic shock with multi-organ dysfunction, previously an indication 
for emergency transplantation, is increasingly becoming a contraindication to transplanta-
tion due to the relatively poor likelihood of successful transplantation. With the option for 
temporization and recover without risking the high perioperative mortality and loss of scarce 
allografts associated with transplantation, the procedure is now being supplanted by mechan-
ical support and then transplantation when the patients are recovered and shock is reversed. 
(3) The overpopulation of waitlists by patients with LVADs with acuity Status 1A who receive 
priority over ambulatory patients will make heart transplantation increasingly unlikely as a 
therapy for the treatment of ambulatory heart failure. (4) The LVAD as a bridge to transplant 
has allowed end stage heart failure to be treated in certain patients as an ambulatory disease 
in an outpatient fashion, rather than a disease requiring continued ICU management [6].
4. Selected subpopulations
In addition to the patient indications listed above, there are a number of unique subpopula-
tions with a need for heart transplantation that would potentially benefit from LVAD as a 
bridging therapy. For one, mechanical circulatory support is an acceptable bridge to trans-
plantation in pediatric patients suffering from heart failure due to structural defects. The 
feasibility of mechanical support as a bridge to transplantation in this subgroup has been 
demonstrated in single- and multi-institutional [19] case reports. For example, a small ret-
rospective case series in 2017 of five patients who underwent VAD placement for congenital 
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heart defects with single ventricle physiology (mean age 12), had a 60% success rate in cardiac 
transplantation without long-standing end organ dysfunction [20]. The factors which play 
into the use of mechanical support in this population are the anatomy of the initial pathology 
and subsequent repairs, as well as pediatric patient size, which may predispose toward the 
use of smaller pumps over others. This relative safety of VAD support in pediatric patients 
has been confirmed in retrospective review of pediatric outcomes in the United Network for 
Organ Sharing database [21]. In general, it is agreed that pediatric patients should be ana-
lyzed on a case-by-case basis; although the rate of postoperative complications is high, the 
initiation of mechanical circulatory support can allow for resolution of end-organ dysfunction 
and allow for aggressive pre-transplant rehabilitation.
With improved management of congenital disease, more pediatric patients are surviving 
into adulthood prior to transplantation; this represents a growing patient subpopulation 
in whom LVAD support may confer a benefit. The American Heart Association opinion 
paper on LVAD in adult congenital disease highlights the challenges of supporting these 
patients; the typical history of many prior surgical and nonsurgical interventions, as well 
as the complex anatomy and physiology of these patients poses a challenge in LVAD imple-
mentation. Additionally, the use of the LVAD in this population is hampered by a lack of 
multi-institutional data regarding selection criteria and surgical technique. It is reinforced 
that the ultimate goal for these patients is cardiac transplant, an intervention after which 
most appropriately-selected adults with congenital heart disease will have survival rivaling 
that of recipients [22].
One unique group that greatly benefits from LVAD placement are those individuals who 
do not initially meet transplant criteria. In this group, entitled, “bridge to candidacy”, the 
LVAD may provide an opportunity to alleviate relative contraindications to transplantation, 
such as active smoking, poor social support, undiagnosed tumors, obesity, and advanced 
lung disease, whereas they would otherwise automatically exclude patients from transplan-
tation. Several months of LVAD support can be enough time for this group to rehabilitate 
and become eligible for a transplant in the future. For example, one study showed the utility 
of LVAD implantation in patients with a body mass index (BMI) greater than 30 during the 
process of losing weight loss in order to become a candidate for eventual transplant [23]. 
Recently, laparoscopic sleeve gastrectomy has been highlighted as an option for patients who 
want to have cardiac transplantation after LVAD implant [24].
Additionally, patients with secondary pulmonary hypertension that is prohibitive of trans-
plant have been shown to benefit from LVAD placement. Very high pulmonary vascular resis-
tances fall over the course of months as the left ventricle is unloaded, allowing for future 
transplant candidacy.
5. Complications
5.1. Readmission
Unfortunately, although LVADs is an effective adjunct in bridging candidates to transplant, 
they are associated with several challenging complications. Mortality and morbidity on the 
heart transplant waiting list has decreased owing to the advancement of VAD technology; 
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candidates supported with contemporary continuous-flow LVADs have favorable waiting list 
outcomes. However, outcomes worsen significantly once a serious LVAD-related complica-
tion occurs. In the current era, the annual rate of readmission for LVAD patients is 65% with 
most occurring in the first 6 months post-implant. The causes for readmission are multifacto-
rial, are commonly due to gastrointestinal bleeding, cardiac causes, infections, and thrombo-
sis (Figure 2).
Hasin et al. reported the findings of a single-institution analysis of readmissions due to com-
plication after the implantation of ventricular assist devices over 2 years. The major primary 
causes in the first 6 months were bleeding (30%, primarily gastrointestinal), cardiac (30%, with 
Figure 2. Complications rates, pulsatile versus two eras of continuous flow (extrapolated from INTERMACS Annual 
reports: Kirklin et. al., 2011, 2012, 2013, and 2014).
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50% from heart failure and 50% from arrhythmias), infections (22%), and thrombosis (14%). 
During the second 6 months, readmissions decrease but after 2 years, bleeding admissions 
were more frequent [25]. A similar retrospective single institution review of VAD complica-
tions demonstrated that progression of the underlying cardiac disease accounted for >50% 
of the rehospitalizations. For LVAD factors, device infection was overwhelmingly the reason 
for admission (57%) [26]. As unplanned hospitalizations are common after VAD implanta-
tion, and increase as one spends more time on mechanical support, avoiding complications 
requires a multidisciplinary team of specialists, close postoperative follow-up, a stable home 
support system, and a well-educated patient population. Here we highlight a number of com-
mon complications after LVAD placement in the patient bridging to heart transplantation.
The INTERMACS annual report describes complication rates.
5.2. Gastrointestinal bleeding
One of the most common causes of admission to the hospital post-implant is gastrointestinal 
bleeding. In the bridge-to-transplant population, large-scale studies have estimated its overall 
prevalence at 22% with an event rate of 0.3 per patient-year [27]. Similar studies of compli-
cations in the bridge-to-transplant population have highlighted major bleeding episodes as 
occurring in 25% of the cohort, with an estimated 70% due to GI sources. Continuous flow 
devices have been implicated, with reduced pulsatility having been found associated with a 
4-fold risk of bleeding compared to those with high pulsatility. Although the mechanisms are 
not fully clear, it is hypothesized that axial flow devices may predispose to increased intra-
luminal vessel pressure, narrowed pulse pressure, and arteriovenous dilation leading to for-
mation of angiodysplasia. Patients on LVAD have been identified as having higher mucosal 
vascularity as well as abnormal vascular architecture in the intestinal submucosa. Additional 
risk factors of angiodysplasia formation and bleeding including older age, female sex and 
ischemic etiology of heart failure [27]. Lesions are primarily located in the upper GI tract, 
although they can be located anywhere along the length of the entire GI tract.
In this setting, initial approaches to mitigate bleeding or prevent further episodes include the 
reduction or discontinuation of antiplatelet agents and anticoagulants and decreases in pump 
speed to allow for aortic valve opening and closure. In the setting of bleeding, treatment may 
involve injecting or clipping of the angiodysplastic area; surgical resection of a bowel segment 
is reserved for emergent or refractory cases. Identifying the bleeding site may pose a chal-
lenge; in the setting of failure to reveal a bleeding source after colonoscopy and esophagogas-
troduodenoscopy, capsule endoscopy has been found to provide little additional diagnostic 
yield [28]); balloon enteroscopy appears to be more effective. Somatostatin may be an effective 
analogue to vasoconstrict the splanchnic bed, suppress gastric acid production and overall 
reduce the frequency of bleeding, and may attenuate the risk of rebleeding when administered 
in the outpatient setting after a bleeding event [29]. In refractory cases, heart transplantation 
may be the only way to restore cardiovascular physiology and ameliorate the bleeding risk.
Of note, there is a significant body of research which shows that LVAD patients develop an 
acquired von Willebrand factor abnormality, which results in subsequent impaired anticoag-
ulation [30]; a recent study demonstrated a reduction in the high molecular weight multimers 
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of the von Willebrand Factor by 30% in patients with a continuous flow LVAD [6]. In a study 
of patients with LVAD placement, Crow and colleagues identified that patients with bleeding 
had significant reductions in von Willebrand factor, ristocetin cofactor, and collagen-binding 
capacity compared to prior to implant, suggesting that bleeding complications after continu-
ous flow LVAD area are function of coagulopathy on a larger scale than just von Willebrand 
factor consumption [31].
5.3. Stroke
While the improved flow dynamics of newer-generation LVAD technology has reduced the 
relative risk of stroke events associated with LVAD usage, the rate per year remains quite 
high. The rate varies between 4 and 10% in most studies, with some modern series highlight-
ing an incidence to be as high as 17%. Stroke after LVAD implantation has found to be associ-
ated with a mortality that is double those of patients who stroke-free [32].
The risk of stroke remains difficult to predict in this population. A number of factors, includ-
ing the type of LVAD used, differences in anticoagulation practice, and the baseline risk of the 
patient population appear contributory. The degree of anticoagulation necessary to prevent 
strokes is not fully clear. Retrospective reviews of patients on both aspirin and warfarin have 
not found subtherapeutic INR to be associated with a stroke, nor has reduced anti platelet 
been highly correlated [13]. In contrast, other studies such as the ADVANCE trial have iden-
tified non-strict adherence to anticoagulation guidelines, including INR <2 and aspirin dose 
of ≤81 mg, as significant risk factors. Future prospective studies will be necessary to identify 
the correct levels of anticoagulation and antiplatelet therapy in the LVAD patient.
The results from initial bridge-to-transplant trials identified a difference in event rates between 
second- and third generation VADs [34]. This is supported by more recent INTERMACS 
annual report notes which note that there has been a decline in the rate of thromboembolic 
events in recent years compared to earlier [33]. The duration of LVAD usage is correlated with 
increasing rate of strokes and mortality; additional contributory factors included a higher 
rate of stroke among patients with mean arterial pressure > 90 mmHg, a history of previous 
strokes, malnutrition, concomitant infection and inflammation, severity of heart failure, and 
prior hematological conditions [34, 35]. A recent study has identified those patients with a 
CHA2DS2-VASc scores greater than or equal to three at the time of implant to be associated 
with an 18% risk of stroke compared to 4% in the population with a score less than 3 [36]. 
Ultimately, although the rate rates have decreased, stroke still represents a significant cause 
of morbidity in the VAD patient.
Current International Society for Heart and Lung Transplant guidelines recommend evalu-
ation of pump parameters as well as CT angiography of the head and neck for diagnosis 
of stroke. In the setting of hemorrhagic stroke, discontinuation or reversal of anticoagula-
tion is advised; interventional radiology or selective thrombolytic agents may be indicated 
in strokes without intracranial hemorrhage [37]. In a small case series of LVAD patients with 
acute ischemic stroke, thrombectomy with or without thrombolytics was not associated with 
intracerebral hemorrhage as a complication. Therapeutic anticoagulation on an LVAD should 
not contraindicate thrombectomy [38].
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5.4. Infection
Infection represents a major limiting factor in the LVAD patient. Post-implantation device related 
infection is associated with significant morbidity, raising costs and length of stay. Modern clini-
cal trials of LVAD efficacy for bridge-to-transplant therapy reported incidence of sepsis between 
20 and 44% patients-year and driveline infection of 10.7–21%, although in some cases this may be 
as high as 30% [39]. Recent retrospective analysis identifies a 1- and 3-year freedom from LVAD 
infection to be 60 and 32%, respectively. High body mass index, diabetes, malnutrition, trauma 
to the exit site, surgical factors, and low lymphocyte count have all been found to increase the 
incidence of infection. Length of implantation of the device is also implicated with longer periods 
of implantation being associated with increasing risk [40]. While early infection tends to present 
as driveline infections, late infections tend to present as bacteremia. Predictors of death in those 
with sepsis include presence of right ventricular failure and non-Gram-positive cocci infection. 
Persistent bacteremia has been found to be a predictor for further events, including strokes.
Recent retrospective analysis of the UNOS database has identified increased mortality among 
LVAD patients with infection. One single-institution study reported a 1-year mortality of 30% 
in those with driveline infections (with 50% of the patients dying from sepsis) [40]. In contrast, 
other small non-matched studies of the bridge-to-transplant population do not identify a sta-
tistically significant reduction in the presence of controlled infection. A retrospective analysis 
reported that pre-transplant driveline infections predicted post-transplant infection at former 
sites and led to longer length of stay without affecting survival [41]. Another retrospective 
analysis demonstrated that the presence of infection during the period of LVAD support did 
not affect post-transplant survival when compared to patients transplanted without prior use 
of an LVAD. We may surmise that while infection does have a negative effect on outcomes 
and may reduce the likelihood of transplantation, especially when refractory to treatment, it 
appears that selected patients with controlled LVAD infection have comparable rates of trans-
plantation as well as early and late post-transplant survival.
Even if infection does not directly lead to morbidity at the time of transplant, there may be 
long-term implications; for example; the surgery may be more challenging, and there may 
be increased allosensitization as Class I and II panel reactive antibodies levels are higher in 
the device infection group. Prevention and control are therefore of paramount importance. 
The proper maintenance of sterility at the driveline exit site is critical; small trials have iden-
tified an absolute risk reduction of 11% after the implementation of a standardized dressing 
kit with silver-impregnated gauze and a standard anchoring device [42]. When infection 
does manifest, there is no defined treatment algorithm; treatment is often multimodal and 
consists of antibiotic therapy combined with local wound care, driveline replacement, and 
device replacement. Omentoplasty has been reported as a surgical option.
Unfortunately, conservative treatment of the infected LVAD with antibiotics therapy and local 
incision and drainage is not associated with clearance on infection in the majority of cases, as 
this approach leaves behind infected hardware; infections on prosthetic surfaces are highly 
resistant to antibiotic treatment due to the reduced penetration of antibiotics into biofilms. In 
many cases, cardiac transplantation may represent the best option for long-term survival in 
patients who are bridge to transplant as it represents the only procedure where all infected 
hardware can be removed.
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5.5. Pump thrombosis
Recent INTERMACS reports and retrospective analyses note that the incidence of pump 
thrombosis has actually increased in the modern era, with current yearly estimates at 2.2–8.4% 
[43]. In 2011, there was an abrupt increase in pump thrombosis associated with the use of the 
HeartMate II [44]. Pump thrombosis may initially be identified by the presence of hemolysis 
with an increasing lactate dehydrogenase (LDH) as well as other hemolysis markers such as 
serum free hemoglobin and bilirubin. While the greatest risk for pump thrombosis occurs in 
the first 3 months after LVAD implantation, that risk continues to increase after 6 months. The 
risk of thrombotic device malfunction, device exchange, and mortality is greater if hemolysis 
occurs within 6 months post-implantation [33].
Modifiable risk factors for thrombus formation have been identified to be poor control of 
hypertension, suboptimal anticoagulation with a mean INR less than 2, and a lack of full-
strength aspirin therapy. In modern series the pump thrombosis is associated with higher 
rates of tamponade, ventricular arrhythmias, hemolysis, venous thromboembolism [34], 
stroke, worsening renal function and poor survival. This is a lethal condition in many cases 
if it is not appropriately treated. Patients with pump thrombosis have a 1-year survival 
rate of 69% compared to 85% for patients who do not experience this complication [34]. 
Identification of high-risk patients remains a priority, with serial X-rays to evaluate cannula 
position, regular monitoring of LDH, and potentially the use of echocardiographic ramp 
test to detect device malfunction [45]. Additionally, pump thrombosis may be diagnosed 
by laboratory signs of hemolysis, evaluation of LVAD waveforms, and acoustic analysis of 
the pump noise.
Aggressive early intervention in patients with pump thrombosis is necessary. In a subset 
of patients with evidence of worsening hemolysis, heparin or bivalirudin infusion may be 
attempted until LDH shows a decline to normal levels and symptoms such as impaired 
renal function resolve. A 50–75% success rate of thrombosis resolution has been reported 
with this method in modern series, although bleeding events (including fatal hemorrhagic 
strokes) were a significant side effect [34]. A recent meta-analysis of medical management 
of pump thrombosis demonstrated thrombolytic therapy to be the most effective therapy 
at 66% salvage, but with a 20% mortality rate–albeit this was only identified when throm-
bolytics were used in conjunction with other anticoagulants. The use of a combination of 
heparin and IIB/IIIA antagonists/direct thrombin inhibitors was associated with high rates 
of major bleeding (35%) and intracerebral hemorrhage (18%). Death was most commonly 
reported after thrombolytics (20%), and the rate of intracerebral hemorrhage was 17%, but 
only when thrombolytics were used in combination with IIB/IIIA antagonists/direct throm-
bin inhibitors [46].
Often, LVAD replacement or ideally heart transplantation are appropriate management 
options [44]; patients that undergo pump exchange for thrombosis have a 44% mortality rate 
at 2 years compared to 31% after primary implant. In those with pump thrombosis who do 
not undergo transplantation or pump replacement, mortality may be as high as 48% [44]. A 
recent study found a 90-day event-free survival of 89% after device exchange compared to 
60.7% after thrombolytic therapy [47].
Heart Transplantation in the Era of the Left Ventricular Assist Devices
http://dx.doi.org/10.5772/intechopen.76935
57
5.6. Right heart failure
Unfortunately, the use of LVAD can be associated with concomitant worsening of right heart 
failure. This is defined as the need of inotropic therapy in order to support right heart func-
tion or use of right sided ventricular assist device (RVAD). Overall, right heart failure in the 
LVAD bridge-to-transplant population can be as high as 10–30%. This condition is associated 
with significant morbidity and mortality, with 71% of patients surviving to 6 months in the 
presence of right heart failure compared to 89% without. Furthermore, a single-institution 
retrospective review has identified 5-year post-transplant survival to be dramatically worse 
in patients who developed late right heart failure during LVAD support compared with 
survival in patients who do not (26% survival with right heart failure versus 87% without) 
Significantly worse post-transplant outcomes and increased mortality among patients with 
a need for both LVAD and RVAD, especially in the setting of long term outcomes, has been 
confirmed in large-scale retrospective database studies [48].
Identifying patients at risk for right heart failure can significantly impact candidate selection 
for LVAD, and has implications regarding timely and appropriate treatment, resource utiliza-
tion and quality of life. Multiple pre-operative risk scores have been developed to estimate 
the risk of right heart failure post-implantation. Identifiers include an elevated central venous 
pressure/pulmonary capillary wedge pressure ratio, increased creatinine blood urea nitrogen, 
INR, need for and number of preoperative vasopressors, transaminitis and hyperbilirubine-
mia [49]. However, low sample sizes and a retrospective study design have typically limited 
the generalizability of these risk scores; recent validation studies of multiple right heart fail-
ure prediction models demonstrated a predictive value that was suboptimal at best [50].
5.7. Allosensitization
One issue with particular significance in the bridge-to-transplant population is that of increas-
ing panel-reactive antibody (PRA) levels after placement of a left ventricular assist device. 
These devices have been shown to induce sensitization in that they are associated with the 
development of circulating anti-HLA antibodies with potential donor reactivity [51]. In the 
era of first generation LVAD support, reports indicated that these elevated levels of antibodies 
were linked to poorer outcomes, notably graft rejection. This association is less clear in mod-
ern studies; while some have indicated that this difference may not be significant, other stud-
ies have noted an increased level of antibody-mediated rejection in the setting of increased 
sensitization [52]. This remains an issue of considerable controversy.
6. Selected issues in bridge-to-transplant
6.1. Cost-effectiveness
With the changing landscape of healthcare in the United States, and a push for single-payer 
healthcare systems similar to that of other industrialized nations such as the United Kingdom 
and Canada, the clinical and cost effectiveness of bridging to transplant using LVAD bears some 
mention. The cost-effectiveness of LVAD support as compared to medical management with ino-
trope support in the bridge-to-transplant candidate has been evaluated in a number of studies.
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The argument can be made against LVAD as a cost-effective treatment strategy for bridge-to-
transplant. While LVAD implantation significantly increases survival compared with medical 
management, the survival of heart transplant candidates treated conventionally while on the 
waiting list has significantly improved in recent years. Therefore, the relative mortality benefit 
of LVAD over medical therapy has become less dramatic. Coupled with the high acquisition 
cost of the device, estimated in some studies to be upwards of $150,000, LVAD does not nec-
essarily provide good value for the money spent according to established thresholds of cost-
effectiveness in many single-payer systems [53].
Initial analyses based on first-generation pulsatile VADs identified LVAD support at the time 
as being more expensive than medical management while appearing less clinically benefi-
cial. However, with the widespread adaptation of second and third-generation LVAD sup-
port, more recent models of cost effectiveness have identified LVAD support as delivering 
greater clinical benefits but at a higher cost. It remains unclear whether LVADs are clearly 
cost-effective from a policy standpoint, but as changes in VAD technology allow for cheaper 
implementation, it is hoped that cost-effectiveness benefits will become more apparent [54].
6.2. Donor allocation in the modern LVAD era
The proportion of new candidates with VADS in the heart transplant waiting list grew from 3 
to 22% from 2007 to 2013 [55]. With the initiation of third-generation LVADs with continuous 
flow, which have fewer complications, improved durability, and smaller size, a significant 
improvement in survival to transplant has been realized [2]. There has been an increasing use 
of VADs for heart transplant over the past decade as a result of these improvements [56], and 
this in turn has had direct implications for the allocation of these scarce organs.
First, there is the issue of transplantation of marginal heart in the LVAD-supported candidate. 
The shortage of donor hearts relative to has led to the increasing use of marginal donor hearts 
for cardiac transplantation in an effort to increase the donor pool, as well as the increased use 
of left ventricular assist devices as bridge-to-transplant. Initially, propensity-matched studies 
of outcomes LVAD versus marginal heart transplantation have favored transplantation for 
better outcomes [57]. However, with the increasing validation of LVAD for extended use, the 
best treatment option and long-term survival outcomes remain unclear. Comparison of these 
populations within the UNOS database demonstrate no significant difference between wait-
ing list survival for patients with LVAD support as a bridge-to-transplant versus survival of 
recipients with marginal donor hearts. Currently, this decision remains within the discretion 
of the transplant team and the patient, but evidence at this time suggests that there could be 
clinical benefits to using LVAD support in order to allow time for better allocation of optimal 
donor hearts as opposed to transplantation with a marginal donor heart [58].
The selectivity afforded to LVAD transplant candidates may be exposing inefficiency within 
the organ allocation system, which does not appear to take into account the increased sur-
vival gains made by patients bridging to transplant with LVAD. A recent study calculated a 
hypothetical Cardiac Allocation Score based on a number of heart failure severity stratifica-
tion systems in VAD and non-VAD patients awaiting transplantation. In non-VAD patients, 
the majority of heart failure severity stratification scores provided accurate risk stratification; 
however, none of the tested scores could predict mortality among VAD-supported patients. 
This is in contrast to earlier evaluations that suggested that at least the INTERMACS score can 
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provide an accurate representation of waiting list mortality in patients receiving continuous-
flow LVAD support. Because the cause of death of LVAD patients is usually unrelated to heart 
failure; heart failure score models may either under- or overestimate the risk of mortality in 
these patients. This, in turn, leads to inaccurate organ allocation, and may come at the cost of 
detrimentally affecting the transplant chances of those patients without LVADs.
The current organ procurement protocol for patients with an LVAD is based on outcome stud-
ies performed in the era in which pulsatile flow devices were used. Based on these outcomes, 
patients implanted with an LVAD awaiting orthotopic heart transplant are status 1B on the 
waiting list, with the option of a 30-day upgrade to status 1A at the discretion of the trans-
plant center. In addition, patients with an LVAD can be upgraded to status 1A in the event of 
a device complication or malfunction. However, it is not clear that patients on LVAD support 
necessarily merit this degree of prioritization. For example, a retrospective review of UNOS 
data revealed that despite being older, less favorable recipients, modern LVAD patients spend 
more time in Status 1A and have greater waitlist survival, which allows LVAD patients to 
receive preferred donor hearts and could allow for better post-transplant survival [59]. In 
particular, a 30-day upgrade of relatively stable LVAD patients to the highest priority level 
(compared with other critically ill patients at Status 1A) may allow for competition between 
patients with different risks of death. With this in mind, there is a concern that LVAD is per-
ceived as a not a bridge to transplant, but a necessary gateway to transplant that is at risk of 
being over utilized. Furthermore, simulations have failed to demonstrate improvements in 
waiting list survival or post-transplant mortality with the Status 1A time allotment [60].
There is still an argument to be made, however, that the risk of VAD complications, includ-
ing thrombosis, infection and sensitization that compromise post-transplant outcomes and 
abrogate any potential benefit that may have been realized by having the VAD; furthermore, 
the aforementioned allocation simulations do not demonstrate increased waiting list mortal-
ity for other candidates who did not have VADs in lieu of other mechanical support. What is 
perhaps the most likely reason for all of these findings is that the allocation system is already 
saturated with candidates at Status 1A and adding more Status 1A time for VAD patients 
would do little to solve the problem–instead, a more efficient method would involve risk 
stratification prioritization of those VAD patients at higher risk for mortality in contrast to 
those stable VAD patients who are at relatively lower risk.
6.3. The future of LVAD support
Studies are ongoing to develop strategies to make smaller and more durable devices, to 
diminish thrombosis, and to minimize surgical complication rates. A miniaturized LVAD 
could reduce the extent of surgical intervention, and would potentially extend the use of the 
LVAD for support of earlier stages of heart failure. Revolutionary future devices currently 
under trial will not require sternotomy or cardiopulmonary bypass; instead they will be 
placed through a minithoracotomy incision into a subclavicular subcutaneous pocket similar 
to a pacemaker. Future technology will ideally allow for completely implantable devices, as 
well as for devices that can provide variable flow in the LVAD, with automated modulation of 
flow in the setting of increased demand such as during exercise.
A return of pulsatile LVAD is also to be expected. There is recent research to suggest that pulse pres-
sure causes vascular responses such as the endothelial production of nitric oxide and vasodilation 
Heart Transplantation60
and improved circulation in the capillary beds of end organs. Comparison of older pulsatile flow 
models suggest a significant hemodynamic to pulsatile flow, with increases in total cardiac out-
put, lower pulmonary pressures, improved coronary flow, and superior left sided unloading 
compared to continuous flow LVADs. Based on these observations, there is now an interest in 
developing algorithms to generate a pulse pressure in an attempt to reduce adverse events associ-
ated with continuous flow LVADs. The HeartMate III represents an exciting disruptive technology 
in this regard because it holds the capacity to generate device-induced pulsatility of blood flows.
7. Conclusion
Left ventricular assist devices represent a useful adjunct in the setting of bridge to orthotopic 
heart transplant. There are still a number of unanswered questions regarding their efficient 
use; most of these questions have come about secondary to the incredible speed innovation 
surrounding these tools as well as their rapid and widespread adoption. There is a critical 
need for continued high quality studies such as large, well conducted, randomized controlled 
trials, particularly addressing the issues of justice in donor organ allocation, patient selection, 
complication avoidance, and needs of high-risk patient groups. Although this technology, 
and the field of heart transplantation in general, is associated with multiple remaining chal-
lenges and complications remain, it is clear that the LVAD is a powerful tool for augmenting 
the failing heart and stabilizing the transplant candidate while a donor organ becomes avail-
able. It represents an important facet in the holistic care of this challenging patient population.
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